Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B Subjects With Decompensated Liver Disease and in the Prevention of Hepatitis B Recurrence Post-Transplantation

NCT00298363 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00298363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00298363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B Subjects With Decompensated Liver Disease and in the Prevention of Hepatitis B Recurrence Post-Transplantation
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2006
Completion date
April 30, 2011
Enrollment
112 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b